Meldoxon (Meldonium Dihydrate)

Meldonium, the active ingredient in Meldoxon, is a metabolic modulator presented as an injectable solution for intravenous use. It is employed in the management of ischemic heart disease, angina pectoris, heart failure and peripheral vascular disease, primarily in adult patients with compromised cardiac perfusion. GNH USA supplies Meldoxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meldoxon acts as a metabolic modulator within the cardiovascular disease spectrum, improving myocardial energy efficiency. - Ischemic heart disease: enhances cardiac performance under reduced oxygen supply. - Angina pectoris: reduces frequency and severity of chest pain episodes. - Heart failure: supports ventricular function and exercise tolerance. - Peripheral vascular disease: improves limb perfusion and reduces claudication symptoms.

Meldoxon may be associated with several adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may resolve with continued therapy. - Dizziness: transient episodes reported. - Hypotension: mild blood pressure reduction. - Insomnia: difficulty initiating sleep. - Skin rash: localized erythema or pruritus.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis requiring immediate medical attention. - Cardiac arrhythmia: new onset or worsening rhythm disturbances. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: acute kidney injury in susceptible individuals.

When prescribing Meldoxon, clinicians should consider patient‑specific factors and monitor for potential complications. - Renal function: assess creatinine clearance before initiation. - Hepatic status: evaluate liver enzymes in patients with known liver disease. - Concomitant antihypertensives: monitor blood pressure for additive hypotensive effect. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Meldoxon may interact with other cardiovascular or metabolic agents, requiring careful assessment.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Strong CYP450 inducers: may reduce therapeutic exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive reduction in heart rate and blood pressure. - Diuretics: monitor electrolyte balance and renal function. - Anticoagulants: observe for increased bleeding tendency.